GeoVax to Present at 2021 BIO Digital
June 07 2021 - 9:00AM
via NewMediaWire --
GeoVax Labs,
Inc. (Nasdaq: GOVX), a biotechnology company
developing human immunotherapies and vaccines against infectious
diseases and cancers, announced today that it has been
selected to deliver a company presentation at 2021 BIO
Digital, the premier biotech event. BIO Digital is scheduled
June 10-11 and June 14-18, 2021.
David Dodd, Chairman & CEO, will present an
overview of GeoVax’s immunotherapy and vaccine research and
development efforts. The presentation will focus on the
Company’s ongoing efforts towards the development of a COVID-19
vaccine capable of addressing the increasing number of SARS-CoV-2
variants. Mr. Dodd will also discuss the Company’s cancer
immunotherapy program and its other vaccine development
programs. The presentation will be available to registered
attendees at 9:00am ET June 10.
Attendees at BIO Digital will be able to view
GeoVax’s company presentation before live meetings in the BIO
One-on-One Partnering™ system begin on June 14. To meet with
GeoVax at BIO Digital, registration information can be
found here.
GeoVax Chairman and CEO, David Dodd, will also
participate in a panel discussion entitled, “Vaccine Business –
Five Minutes of Fame or Five-Time Oscar Winner?” The panel
discussion and live Q&A chat is scheduled for Tuesday, June 15,
at 11:05am ET.
About GeoVax
GeoVax is a clinical-stage company developing
vaccines against infectious diseases and cancer. GeoVax’s current
development programs are focused on preventive vaccines against
COVID-19, Zika Virus, hemorrhagic fever viruses (Ebola, Lassa,
Marburg and Sudan), HIV and malaria, as well as therapeutic
vaccines against multiple cancers.
Through the Company’s novel Modified Vaccinia
Ankara-Virus Like Particle (MVA-VLP) based platform, MVA, a large
virus capable of carrying several vaccine antigens, expresses
proteins that assemble into VLP immunogens within the person
receiving the vaccine. The production of VLPs in vivo mimics virus
production in a natural infection, stimulating both the humoral and
cellular arms of the immune system to recognize, prevent, and
control the target infection. The MVA-VLP derived vaccines elicit
durable immune responses in the host similar to a live-attenuated
virus, while providing the safety characteristics of a
replication-defective vector.
About BIO
BIO is the world's largest advocacy organization
representing biotechnology companies, academic institutions, state
biotechnology centers and related organizations across the United
States and in more than 30 other nations. BIO members are involved
in the research and development of innovative healthcare,
agricultural, industrial and environmental biotechnology products.
BIO also produces the BIO
International Convention, the world’s largest gathering
of the biotechnology industry, along with industry-leading investor
and partnering meetings held around the world.
GeoVax Labs,
Inc.678-384-7220investor@geovax.com
GeoVax Labs (NASDAQ:GOVX)
Historical Stock Chart
From Mar 2024 to Apr 2024
GeoVax Labs (NASDAQ:GOVX)
Historical Stock Chart
From Apr 2023 to Apr 2024